A literature review and analysis of inhalation bioavailability data for large therapeutic proteins was con-ducted in order to develop a practical estimate of the inhalation bioavailability of these drugs. This value is incorporated into equations used to derive occupational exposure limits(OELs) to protect biophar-maceutical manufacturing workers from systemic effects. Descriptive statistics implies that a value of 0.05, or 5 % is an accurate estimate for large therapeutic proteins (molecular weight ≥ 40 kDa). This estimate is confirmed by pharmacokinetic modeling of data from a human daily repeat-dose inhalation study of immunoglobulin G. In conclusion, we recommend using 5 % bioavailability by inhalation when developing OELs for large therapeutic proteins. K e y w o r d s: inhalation bioavailability; occupational exposure limit; OEL; therapeutic proteins I n t r o d u c t I o n Biologics constituted>30 % of approved pharmaceu-ticals, with 179 new biologics (that are not vaccines or blood products) approved between 1993 and early 2013 (Sathish et al., 2013; U. S. FDA, 2013). These drugs have offered novel and effective treatment
Is data on this page outdated, violates copyrights or anything else? Report the problem now and we will take corresponding actions after reviewing your request.